RecruitingNot Applicable

The Use of Combined Motor Imagery and Action Observation to Evaluate the Influence on Functional Parameters Such as Strength, Range of Motion, Pain or Fear of Movement Among Others, in Females Breast Cancer Survivors.

Spain108 participantsStarted 2025-02-25

Plain-language summary

The aim of this study is to evaluate the effectivity of the combined motor imagery and action observation therapies to improve functional parameters such as strenght, range of motion, pain or fear of movements among others in relation to upper limb in breast cancer survivors. The main question it aims to answer is: Will a combined therapy of motor imagery and action observation improve the strenght, rang of motion, pain, limb diameter and fear of movement of the upper limb in breast cancer survivor females? The participants will be part of the IM-OA23 proyect that consist on seeing some diferent videos about upper limb mobility and then they'll have to imagine the movements and to performed themselves. Researches will compare two groups (control group and intervention group) to evaluate the diferences between them.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female, over 18 years, have suffered breast cancer, have ended active treatments (chemotherapy, radiotherapy, surgery), have pain or functional limitation or lymphedema at upper limb afected. Exclusion Criteria: * males, people with active treatments ongoning, other types of cancer, recurrence or metastasis of cancer

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Sthrength

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Range of Motion

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Pain intensity

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Limb diameter

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Fear of movement

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Imagery

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Trial details

NCT IDNCT07067710

SponsorFundacion Miguel Servet

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-28

Contact for this trial

Pilar Arnal-Vallés, Candidate PhD

+34 948166117 pilararnal3b@gmail.com

View on ClinicalTrials.gov More Breast Cancer Survivor trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Sthrength

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Range of Motion

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Pain intensity

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Limb diameter

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Fear of movement

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after

Imagery

Timeframe: From enrollement to the end of the treatment at 6 weeks and 3 month after